Curis | CRIS - Operating Profit


Curis reported $-7.88M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 1.11B 1.65B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Curis USD -7.88M 4.63M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Takeda JPY 168.82B 479.89B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -41.48M 23.2M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024